Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05441514 | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04167917 | NTX-301 in MDS/AML | completed | Phase 1 | 22 | University of Alabama at BirminghamOTHER | 1 | May 1, 2026 | clinicaltrials |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant |
| completed |
| Phase 3 |
| 174 |
| Fred Hutchinson Cancer CenterOTHER |
| 3 |
| Apr 30, 2026 |
| clinicaltrials |
| NCT04819854 | Single and Multiple Ascending Dose Study With EP395 | completed | Phase 1 | 78 | EpiEndo PharmaceuticalsINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02315612 | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | completed | Phase 1 | 134 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03068819 | Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 62 | Washington University School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03298321 | Action of the Vidaza on the Atrial Fibrillation(AVIFA) | completed | — | 1 | Hospices Civils de LyonOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03009240 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02320656 | Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015(HEMATO-BIO) | completed | N/A | 650 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05858593 | Positive Youth Development in the Metaverse | completed | N/A | 32 | University of GeorgiaOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04625413 | A Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists(UR-GOAL 1) | completed | N/A | 15 | University of RochesterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04996160 | Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 2 | Tanja Andrea GruberOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04641910 | Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia(FLAMVAL) | completed | — | 201 | Nantes University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03466294 | Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML | completed | Phase 2 | 42 | University of Colorado, DenverOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04102020 | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy(VIALE-M) | completed | Phase 3 | 112 | AbbVieINDUSTRY | 19 | Apr 8, 2026 | clinicaltrials |
| NCT05972577 | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | completed | N/A | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02204085 | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 33 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05474170 | Impact of 2 Resuscitation Sequences on Management of Simulated Pediatric Cardiac Arrest | completed | N/A | 28 | Geneve TEAM AmbulancesOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 / Phase 2 | 12 | CRISPR TherapeuticsINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04745676 | A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome(SICG) | completed | N/A | 36 | University of RochesterOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04088890 | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | completed | Phase 1 | 52 | Matthew FrankOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04339101 | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | completed | Phase 2 | 59 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06209190 | Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation | completed | N/A | 14 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04107727 | Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | completed | Phase 2 | 273 | PETHEMA FoundationOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03232268 | HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies(MICROSTEM) | completed | Phase 1 | 25 | Institut Paoli-CalmettesOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03226418 | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | completed | Phase 2 | 75 | University of NebraskaOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT01758042 | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders(BMT) | completed | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT02975869 | A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia | completed | N/A | 160 | Massachusetts General HospitalOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03751072 | Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)(FRENCH-CYTO) | completed | — | 92 | Group for Research in Adult Acute Lymphoblastic LeukemiaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02730299 | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS | completed | Phase 3 | 125 | Gamida Cell ltdINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT04620681 | CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML | completed | Phase 1 / Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05350787 | Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL | completed | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06565975 | Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France(RELION) | completed | — | 112 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03165851 | Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia | completed | — | 320 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05739409 | LILRB4 STAR-T Cell Therapy for Monocytic Leukemia | completed | N/A | 1 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05987696 | Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia | completed | Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06181734 | Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC(CONFIDHENCE) | completed | — | 8 | iOMEDICO AGINDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06705530 | A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders | completed | Phase 1 / Phase 2 | 58 | National Research Center for Hematology, RussiaNETWORK | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05694364 | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | completed | Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05906914 | Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia(CHA) | completed | Phase 2 | 65 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06578351 | TRacking Atopic Dermatitis Infants and Their Microbiome (TRAM)(TRAM) | completed | — | 60 | Danone Asia Pacific Holdings Pte, Ltd.INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05784415 | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell(CS22-03) | completed | — | 30 | AIDS Malignancy ConsortiumNETWORK | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04800510 | Iterative Design of Custom Dynamic Orthoses(PRMRP-Norms) | completed | N/A | 9 | University of IowaOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07379528 | Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome | completed | — | 70 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07036809 | Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia | completed | — | 90 | Muhamed Ahmed Abdelmoaty Muhamed AlhagrasyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04681105 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | completed | Phase 1 | 13 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | University of Colorado, DenverOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05622682 | Vaccine Immune Recovery After Leukemia(VIRAL) | completed | — | 89 | Children's Hospital of PhiladelphiaOTHER | 1 | Jan 26, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 5, 2026source: clinicaltrials